HOME >> MEDICINE >> NEWS
Overactive bladder episodes completely controlled in 40 percent of elderly patients treated with once-a-day Oxybutynin

Elderly patients suffering from overactive bladder can significantly and safely reduce the symptoms of their condition by taking a once-a-day, extended-release formulation of oxybutynin chloride (Ditropan XL®), according to a study conducted by the Cleveland Clinic Foundation scheduled for presentation at the 2000 Annual Scientific Meeting of the American Geriatrics Society.

In the study, 40 percent of patients age 65 and older taking extended-release oxybutynin reported no incontinence episodes, while the average reduction in the weekly number of incontinence episodes for the elderly patients in the study was 82 percent.

"We found that elderly patients not only benefit by significantly reducing or eliminating their incontinence episodes when taking the extended-release formulation of oxybutynin, they also can do so safely and tolerate the drug very well. This is good news for this patient population, which frequently must deal with taking multiple medications and experiencing worrisome side effects," said Rodney Appell, M.D., study author and head, Section of Voiding Dysfunction and Female Urology at the Cleveland Clinic Urological Institute.

Overactive bladder is a common and chronic condition that affects an estimated 17 million Americans. The condition is characterized by urge urinary incontinence (sudden and involuntary loss of bladder control resulting in wetting accidents), urgency (the urgent need to empty the bladder) and frequency (frequent urination). Ditropan XL is the first and only once-a-day treatment for overactive bladder approved by the FDA and is marketed by ALZA Corporation and UCB Pharma.

For the study, investigators analyzed three clinical trials comparing different doses of extended-release and immediate-release oxybutynin in 159 patients older than 65 and in 261 patients age 18 to 65. All of the 420 patients suffered from overactive bladder.

During the clinical trials, researchers adjusted the
'"/>

Contact: Jim Armstrong, Cleveland Clinic
216-444-9455
Porter Novelli
19-May-2000


Page: 1 2 3

Related medicine news :

1. Overactive bladder symptoms affect sexual activity of women says Univ. of Pittsburgh study
2. New substance that improves the photodetection of bladder cancer gains market approval
3. Study examines three-day antibiotic regimens for treating bladder infection in women
4. New study tests amitriptyline for painful bladder syndrome
5. New test improves detection of bladder cancer
6. Faster, less expensive test proven more effective in detecting bladder cancer
7. Promise of bladder pacemaker for people with spinal cord injury
8. Use of estrogen therapy may increase risk for gallbladder disease
9. FDA approves Enablex for treatment of overactive bladder
10. Long-term data show benefit of DETROL LA as first-line therapy for overactive bladder
11. Scientists begin validation study of test to detect recurrence of bladder cancer

Post Your Comments:
(Date:4/23/2014)... State University researcher is looking to give exercise enthusiasts ... her latest research shows that a cyber buddy can ... Games for Health Journal , is the first to ... better motivator during exercise, a software-generated partner also can ... that isn,t real can still motivate people to give ...
(Date:4/23/2014)... University researchers have identified an important enzyme pathway that ... too few chromosomes, a condition that has been directly ... associate professor of biochemistry, found that near the end ... enzyme that ensures any breaks in DNA are fully ... genome to daughter cells. This process helps safeguard against ...
(Date:4/23/2014)... could help doctors predict which patients might suffer potentially ... The program, which assesses brain scans using pattern recognition ... passport control, has been developed by researchers at Imperial ... the Wellcome Trust, which used the software are published ... Stroke affects over 15 million people each year worldwide. ...
(Date:4/23/2014)... displayed in the popular Swedish children,s TV show ... foods. A new study from the University of ... TV programmes as well as the link between ... status. , Steingerdur Olafsdottir,s doctoral thesis focuses on ... children,s TV show Bolibompa. Healthy foods dominated in ...
(Date:4/23/2014)... about an increase in adolescents, marijuana use following the ... relief. According to a new study at Rhode Island ... states with and without medical marijuana laws, legalizing the ... The study is published online in advance of print ... , "Any time a state considers legalizing medical marijuana, ...
Breaking Medicine News(10 mins):Health News:Cyber buddy is better than 'no buddy' 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
Cached News: